Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Full approval will depend on verification of clinical benefit in a confirmatory trial
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Subscribe To Our Newsletter & Stay Updated
